Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Depreciation & Amortization (CF) (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • Quarterly Depreciation & Amortization (CF) rose 8.2% to $1.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Sep 2025, up 11.21% year-over-year, with the annual reading at $4.2 million for FY2024, 33.08% up from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $1.2 million at Xtant Medical Holdings, down from $1.2 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $1.2 million in Q2 2025, with the low at $281000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $706631.6, with a median of $803000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) tumbled 45.26% in 2021, then soared 216.82% in 2023.
  • Over 5 years, Depreciation & Amortization (CF) stood at $291000.0 in 2021, then rose by 10.31% to $321000.0 in 2022, then skyrocketed by 216.82% to $1.0 million in 2023, then rose by 12.88% to $1.1 million in 2024, then rose by 1.13% to $1.2 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $1.2 million, $1.2 million, and $1.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.